Background: Lumateperone (ITI-007) is a first-in-class investigational agent in development for the treatment of schizophrenia. Acting synergistically through serotonergic, dopaminergic and glutamatergic systems, lumateperone represents a new approach to the treatment of schizophrenia and other neuropsychiatric disorders. Lumateperone is a potent antagonist at 5-HT2A receptors and exhibits serotonin reuptake inhibition. Lumateperone also binds to dopamine D1 and D2 receptors acting as a mesolimbic/mesocortical dopamine phosphoprotein modulator (DPPM) with pre-synaptic partial agonism and post-synaptic antagonism at D2 receptors and as an indirect glutamatergic (GluN2B) phosphoprotein modulator with D1-dependent enhancement of both NMDA and AMPA currents via the mTOR protein pathway. Lumateperone demonstrated antipsychotic efficacy in two well-controlled clinical trials and was found to be well tolerated with a safety profile similar to placebo in all trials conducted to date.
F47. COGNITIVE REMEDIATION AND PHYSICAL EXERCISE IN MULTI-EPISODE
Background: Cognitive remediation (CR) and physical exercise have separately shown promising results in schizophrenia cognitive improvement, despite this, the impact on daily functionality is still limited. Physical exercise increases Brain Derived Neurotrophic Factor (BDNF) levels, promoting neuronal and cognitive plasticity, which can maximize the impact of CR. We are conducting a randomised controlled trial to determine the efficacy of an intensive program that combines CR and physical exercise on cognition and related outcomes for patients with schizophrenia. In addition, we investigate functional and structural brain effects of this intervention and its association to BDNF. Methods: This study protocol describes a randomized controlled trial in which 74 patients are randomly assigned to either CR and physical exercise or CR and health promotion. The interventions are 12-week long and consist of three weekly sessions (90 min of CR and 40 min of either aerobic exercise or health promotion). To be included in the study, patients must be diagnosed with schizophrenia or schizoaffective disorder, aged 28-60 years, and do low physical activity, as measured by International Physical Activity Questionnaire, IPAQ. Exclusion Criteria for participation in the study are the presence of neurological or substance use disorders, IQ < 70 and somatic illnesses that contraindicate physical exercise. Healthy control participants (n=18) are screened for the presence of lifetime Axis I psychotic disorders and for the presence of a first-degree relative with schizophrenia. Primary outcome measures are cognitive performance, functional outcome, negative symptoms, BDNF levels and neuroimaging measures. Secondary outcome measures are quality of life and metabolic parameters. All measures are blindly assessed at baseline, at 3 months follow up and at 15 months follow up. This trial was approved by the Comité Ètic d'Investigació Clínica de l'Hospital del Mar (CEIC) 2015/6209/I Results: This poster is a study protocol. We will correct data from now on. Discussion: The results of this trial will provide valuable information about whether cognitive remediation efficacy for patients with schizophrenia can be enhanced by aerobic exercise-induced BDNF upregulation. Results: Among 120 patients, the mean age (SD) was 36.8 years (10.4) and 71.7% were males. Of these, 59 were randomized to the BT group and 61 to the SCIT group. The mean age of participants was 36.8 years. 85.8% were receiving government benefit and 50% lived in supported housing. 71.7% were males. Pre/Post data will be presented on the 91 participants who completed the study. Results examining the primary outcome measure found there was insufficient evidence to conclude that the SCIT group was significantly different compared to BT group in terms of emotion recognition (BLERT scores) (SCIT vs BT change: 0.437, 95% CI: -0.14 to 1.01; P = 0.136). There was an overall effect of time where both treatments showed a steady improvement over time from baseline to endpoint and the effect was maintained at the three-month follow-up. There was no significant time x treatment group interaction which indicated that there was no difference in patterns of change in the treatment group over time. Data on secondary outcomes is currently being analysed. Discussion: In this medium sized RCT of social cognition interaction therapy that used an active control, (BT) and standardised measure of emotional recognition, (BLERT) we found no significant difference between the interventions in our primary outcome measure of emotional recognition. Improvement in emotional perception has been found in the majority of studies of social cognitive interventions for schizophrenia. More specifically our results differ to those of Hasson-Ohayon who found significant improvement in emotion recognition in a RCT of SCIT with social mentoring compared with social mentoring alone in people diagnosed with schizophrenia, schizoaffective disorder, depression or bipolar disorder (Hasson-Ohayon 2014) . This study is the largest RCT of SCIT to find a negative result in regards to emotion perception. Background: The Meta-Cognitive Training (MCT) is a psychological intervention that combines psychoeducational components and cognitive behavioural therapies with a meta-cognitive approach. The MCT (Moritz and Woodward, 2007) focuses on different cognitive biases, theory of mind and attribution bias, as well as on the predictive value of depressed mood and low self-esteem on paranoid ideation. The MCT has result effective for people with schizophrenia in order to improve symptoms, cognitive insight, jumping to conclusions, memory and quality of life. However, less information is regarding the effectiveness of MCT in first episode psychosis. On the other hand, gender has an important role in psychosis, nevertheless the effect of gender in the effectiveness of MCT has not been proved. The aim of the study is to assess the effectiveness of MCT regarding symptoms and cognitive insight in people with first episode psychosis, considering the effect of gender. Methods: A multicenter, randomized, controlled clinical trial was performed. A total of 122 patients were randomized to an MCT or a psychoeducational intervention. The sample was composed of people with a recent onset of psychosis, recruited from 9 public centers in Spain. The treatment consisted of 8 weekly sessions for both groups. Patients were assessed at three time-points: baseline, post-treatment, and at six months of follow-up. The evaluator was blinded to the condition of the patient. Symptoms were assessed with the PANSS and cognitive insight with the BCIS. A regression model for repeated measures was performed with the SPSS by gender. Results: The sample was composed by 85 men and 37 women, although 53 men and 21 women completed the treatment and the follow-up. Both psychoeducational and MCT group improved in positive symptoms at post-treatment and follow-up (p<0.05-0.001) with higher effect sizes in the MCT group (0.53 versus 0.38). Regarding negative symptoms the MCT group improved in the follow-up (p<0.001) and general symptoms MCT improved in the post-treatment and follow-up (p<0.001). Cognitive insight was higher in people who attended the MCT, in self-certainty in the posttreatment (p<0.05), self-reflectiveness in the follow-up (p<0.05) and the composite index in both assessments (p<0.05).
F49. EFFECTIVENESS OF THE META-COGNITIVE TRAINING IN PEOPLE WITH FIRST-EPISODE PSYCHOSIS: DOES GENDER MATTER
Considering the results by gender, men of both groups improve more in positive, negative and disorganized symptoms of the PANSS (p<0.001-0.046) while women improve in positive symptoms. A tendency of interaction between group and affective symptoms was found only in women (p=0.062), improving more women of the MCT group. Regarding cognitive insight, women of the MCT group improve more in self certainty and total BCIS compared with the psychoeducational group (p<0.001-0.022). Discussion: MCT could be an effective psychological intervention for people with a recent-onset of psychosis for the improvement of cognitive insight and psychotic symptoms. It seems that women could benefit more from the MCT intervention than men in reduction of affective symptoms and in the improvement of cognitive insight.
